# CGBIO to supply NOVOSIS to LifeHealthcare in Australia

CGBIO announced an agreement with LifeHealthcare to supply its rhBMP-2 bone graft product NOVOSIS for the Australian and New Zealand markets, with potential revenue of KRW 200 billion.

- Type: Contract
- Announced: 2020-09-16
- Where: Australia and New Zealand, Australia
- Status: announced
- Products: NOVOSIS recombinant human bone morphogenetic protein-2 (rhBMP-2) bone graft
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [LifeHealthcare Group Limited](https://endata.com/companies/23464.md) (customer)
- [CGBIO](https://endata.com/companies/42255.md) (supplier)

## Sources

- [cgbio.co.kr](http://www.cgbio.co.kr/en/13697), 2020-10-12: "We have an aim to expand biopharmaceutical business in orthopedics and neurosurgery by strong sales of NOVOSIS."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.